{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.4","upperLimit":"36.3","value":"13.3"},{"groupId":"OG001","lowerLimit":"0.3","upperLimit":"26.4","value":"6.3"},{"groupId":"OG002","lowerLimit":"2.7","upperLimit":"23.2","value":"9.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"31"}],"units":"Participants"}],"description":"ORR is defined as the number of participants with stringent compete response \\[SCR\\], complete response \\[CR\\], very good partial response \\[VGPR\\], and partial response \\[PR\\])/number of participants in arm, expressed as a percentage. Confidence intervals computed using the Clopper and Pearson method. SCR=CR plus normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. CR=Negative immunofixation on serum and urine and 5% or fewer plasma cells in bone marrow. VGPR=Serum and urine monoclonal (M) protein detectable by immunofixation but not on electrophoresis or 90% reduction in serum M protein level plus urine M protein level \\<100 mg/24 hour. PR=50% reduction of serum M protein and reduction in 24-hour urinary M protein by 90% or to \\<200 mg/24 hour","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants in 2 arms were enrolled sequentially. The first group of participants received elotuzumab intravenously at a dose of 20 mg/kg on Days 1 and 8 per 28-day cycle for Cycle 1 and then on Day 1 only in subsequent cycles.","id":"OG000","title":"Elotuzumab, 20 mg/kg"},{"description":"Participants in the second group received elotuzumab intravenously at a dose of 10 mg/kg weekly per 28-day cycle in Cycles 1 and 2, then on Days 1 and 15 in subsequent cycles.","id":"OG001","title":"Elotuzumab, 10 mg/kg"},{"description":"All participants on Elotuzumab therapy. Comprised of both the 20mg/kg and 10mg/kg arms","id":"OG002","title":"Elotuzumab, All Dosages"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to date of progression or objective response (assessed up to August 2017, approximately 59 months)","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}